PRISMA: Clinical AI Risk Intelligence Platform

---

PRISMA is a clinically validated NLP-based platform designed to detect early deterioration and generate interpretable risk trajectories in chronic disease — initially focused on chronic kidney disease (CKD) and cardio-renal syndromes (CRS), with modular scalability across additional high-burden chronic conditions.

ospitals manage millions of chronic disease patients without reliable early risk detection tools.

In such conditions:

• Early deterioration is often first documented in free-text clinical notes
• Multimorbidity patterns are missed
• Risk signals remain buried in unstructured documentation
• Structured parameters (eGFR, UACR) detect damage late

As a result:
High-risk patients are identified too late.
Preventable hospitalizations persist.
Clinical workflows remain reactive rather than predictive.

PRISMA is a TRL6-validated NLP-based clinical decision-support engine that:

• Extracts early deterioration signals from unstructured clinical notes
• Integrates structured laboratory data
• Incorporates molecular biomarkers when clinically indicated
• Generates interpretable risk trajectories
• Embeds into hospital EHR workflows

PRISMA has demonstrated:

• Strong predictive performance for defined clinical endpoints
• Detection of semantic deterioration signals not captured in structured nephrology parameters
• Extraction of multimorbidity escalation patterns
• Feasibility of integration into hospital EHR environments

PRISMA’s architecture is:

• Disease-modular
• Multimodal (notes + labs + optional proteomic biomarkers)
• Interoperable
• Designed for MDR-compliant SaMD deployment

PRISMA's structured semantic framework enables disciplined expansion into additional chronic inflammatory and multimorbidity domains where early risk signals are embedded in unstructured documentation.

PRISMA creates:

✔ Predictive risk intelligence embedded within hospital workflows
✔ Scalable SaaS revenue with modular disease expansion
✔ Proprietary longitudinal multimodal datasets
✔ Pharma collaboration opportunities in clinical trial desiign
✔ Acquisition pathways within clinical workflow and EHR ecosystems

2026:

• CKD institutional deployments
• Cardio-renal module development

2027:

• MDR-aligned software architecture
• Multi-center validation publication

2028:

• Expansion into additional chronic disease verticals
• Strategic enterprise partnerships

We are seeking:

• Hospital pilot partners
• Enterprise EHR integration partners
• Strategic pharma collaborations
• Institutional investors